After a long-awaited deal, Nestle has confirmed its successful take-over of Novartis Medical Nutrition to the tune of US$2.5bn. Not only will the deal strengthen nestle's health and nutrition...
Read the full post.
The National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH) will grant a total of $20.65 million to research institutions around the country in 14 High-End...
Read the full post.
The International Center for Advanced Renewable Energy and Sustainability (I-CARES) has been spearheaded by the Washington University in St. Louis to encourage and coordinate university-wide and...
Read the full post.
Biotech giant Amgen, Inc has agreed to buy Ilypsa, a privately-held, Sand Francisco based firm focusing on the development of drugs against kidney disease, for $420 million. Ilypsa's lead drug...
Read the full post.
Google has invested $39 million in 23andme, a privately held, early-stage personal genetics company co-founded by Anne Wojcicki, who is married to Google, Inc. co-founder Sergey Brin. From the 23andme...
Read the full post.
Novartis AG has acquired worldwide exclusive rights to a novel vaccine candidate against nicotine addiction from Cytos Biotechnology AG for up to 600 million Swiss francs (US$500 million; €366...
Read the full post.
The US FDA has licensed Sanofi-Aventis' H5N1 vaccine (pdf file of the press release here), the first Avian influenza vaccine for humans in the U.S. The licensure of this vaccine was based on a...
Read the full post.
Ernst & Young has released Beyond Borders 2006, its annual review of the biotechnology sector globally, as well as of major regional markets, including the Americas, Asia-Pacific, and Europe....
Read the full post.
Merck & Co., Inc. has licensed Coley Pharmaceutical's VaxImmune(TM) vaccine adjuvant for an upfront license fee of $4 million, and milestone fess of up to $33 million plus royalties....
Read the full post.
MedImmune, the makers of the inhaled influenza vaccine FluMist, is considering acquisition offers from third parties. It has hired Goldman Sachs & Co. and the law firm Dewey Ballantine to help...
Read the full post.
Roche and Transgene will collaborate to develop and market products from Transgene's vaccine program against HPV-mediated diseases, including Transgene's main vaccine candidate TG 4001,...
Read the full post.
A study published this week at Nature Biotechnology takes a closer look at the current state of biotechnology in India. This study focuses on the private sector firms at the heart of innovation...
Read the full post.
ConocoPhillips is investing $22.5 million on a research program at the Iowa state University to develop technologies that produce biorenewable fuels. The grant consists of an initial $1.5 million in...
Read the full post.
According to a study released by the Center for Venture Research at the University of New Hampshire, angel investing picked up in 2006, and is likely to continue to do so in 2007. And biotech is one...
Read the full post.
GlaxoSmithKline PLC had invested S$20 million (US$13 million; €9.8 million) in a new laboratory in Singapore's biotechnology hub, Biopolis, as part of its Center for Research in Cognitive and...
Read the full post.
The US FDA has approved Novartis' new hypertension drug, Tekturna (aliskiren), a direct renin inhibitor. A once-daily oral tablet therapy, Tekturna acts by blocking renin, an enzyme responsible...
Read the full post.
In a policy paper published in PLoS Medicine, Loane Skene, Professor of Law at the University of Melbourne, Australia, discusses whether it is ethical for scientists to conduct or benefit from...
Read the full post.
Fierce Biotech has released its "Top Five Regions Targeting Biotech Companies" for 2007. This is unquestionably a highly subjective list drawn from the headlines that we scour every day for...
Read the full post.
Bangalore-based life sciences company Avestha Gengraine Technologies has closed a $32.5 million round of venture funds from four investors led by Fidelity International, which gained a 10 percent...
Read the full post.
